Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 2Urethral Neoplasms 1Ureteral Neoplasms 1Neoplasms 1Carcinoma, Transitional Cell 1Breast Neoplasms 1Acrocephalosyndactylia 1

Interventions

Gemcitabine 4pembrolizumab 3Docetaxel 3aflibercept 2Trastuzumab 2Specimen Handling 2Cisplatin 2Carboplatin 2vinflunine 1tipifarnib 1erdafitinib 1enzalutamide 1entinostat 1enfortumab vedotin 1cabozantinib 1avelumab 1Thalidomide 1Sorafenib 1Ramucirumab 1Radiotherapy 1Platinum 1Nivolumab 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Ipilimumab 1Introns 1Interleukin-12 Subunit p35 1Interleukin-12 1Interferon-alpha 1Interferon alpha-2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Urethral Neoplasms × erdafitinib × Clear all
NCT04963153 2026-05-13

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

National Cancer Institute (NCI)

Phase 1 Active not recruiting
24 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡